CA2842464C - Systeme et procede d?analyse d?echantillons marques au moyen de la 5, 10, 15, 20 tetrakis (4-carboxyphenyle) porphine (tcpp) - Google Patents
Systeme et procede d?analyse d?echantillons marques au moyen de la 5, 10, 15, 20 tetrakis (4-carboxyphenyle) porphine (tcpp) Download PDFInfo
- Publication number
- CA2842464C CA2842464C CA2842464A CA2842464A CA2842464C CA 2842464 C CA2842464 C CA 2842464C CA 2842464 A CA2842464 A CA 2842464A CA 2842464 A CA2842464 A CA 2842464A CA 2842464 C CA2842464 C CA 2842464C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- tcpp
- dysplastic
- biological sample
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- HHDUMDVQUCBCEY-UHFFFAOYSA-N 4-[10,15,20-tris(4-carboxyphenyl)-21,23-dihydroporphyrin-5-yl]benzoic acid Chemical compound OC(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc([nH]2)c(-c2ccc(cc2)C(O)=O)c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc1[nH]2 HHDUMDVQUCBCEY-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 157
- 206010036790 Productive cough Diseases 0.000 claims abstract description 33
- 210000003802 sputum Anatomy 0.000 claims abstract description 33
- 208000024794 sputum Diseases 0.000 claims abstract description 33
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 25
- 230000004907 flux Effects 0.000 claims abstract description 16
- 230000005284 excitation Effects 0.000 claims abstract description 14
- 210000002540 macrophage Anatomy 0.000 claims abstract description 5
- SMOZAZLNDSFWAB-UHFFFAOYSA-N 4-[10,15,20-tris(4-carboxyphenyl)-21,24-dihydroporphyrin-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=CC(N=1)=C(C=1C=CC(=CC=1)C(O)=O)C1=CC=C(N1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)C(O)=O)=C2N=C1C=C2 SMOZAZLNDSFWAB-UHFFFAOYSA-N 0.000 claims description 63
- 239000000523 sample Substances 0.000 claims description 27
- 239000012472 biological sample Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000002372 labelling Methods 0.000 claims description 14
- 230000003595 spectral effect Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 206010058314 Dysplasia Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012216 screening Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000003116 impacting effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 241001522301 Apogonichthyoides nigripinnis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- CIBMHJPPKCXONB-UHFFFAOYSA-N propane-2,2-diol Chemical compound CC(C)(O)O CIBMHJPPKCXONB-UHFFFAOYSA-N 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Abstract
Un mode de réalisation de la présente invention a pour objet un procédé permettant de déterminer si un échantillon d?expectoration contient des cellules dysplasiques ou carcinomiques par l?obtention d?un échantillon d?expectoration contenant des cellules. L?échantillon d?expectoration est marqué au moyen de la TCPP pour colorer les cellules suspectées d?être dysplasiques ou carcinomiques. L?échantillon d?expectoration marqué est excité avec une longueur d?onde d?excitation de la lumière d?environ 475 nm +/- 30 nm et une émission à environ 560 nm +/- 30 nm est détectée à partir des cellules identifiées comme étant des macrophages. Un imageur effectue une mise au point sur la membrane plasmatique d?une ou plusieurs cellules suspectées d?être dysplasiques ou carcinomiques et une émission à environ 655 nm +/- 30 nm, si elle est présente, est détectée pour les cellules marquées à la TCCP de l?échantillon d?expectoration après mise au point sur la membrane plasmatique des cellules de l?échantillon d?expectoration. Un flux de photons pour chaque pixel d?un capteur est mesuré pour obtenir une valeur pour la cellule imagée. La valeur mesurée est relevée pour déterminer si une cellule est cancéreuse ou dysplasique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/042481 WO2011009137A1 (fr) | 2009-07-17 | 2010-07-19 | Système et procédé danalyse déchantillons marqués au moyen de la 5, 10, 15, 20 tétrakis (4-carboxyphényle) porphine (tcpp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2842464A1 CA2842464A1 (fr) | 2011-01-20 |
| CA2842464C true CA2842464C (fr) | 2019-01-22 |
Family
ID=50138019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2842464A Active CA2842464C (fr) | 2010-07-19 | 2010-07-19 | Systeme et procede d?analyse d?echantillons marques au moyen de la 5, 10, 15, 20 tetrakis (4-carboxyphenyle) porphine (tcpp) |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2842464C (fr) |
-
2010
- 2010-07-19 CA CA2842464A patent/CA2842464C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2842464A1 (fr) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150160197A1 (en) | System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP) | |
| Mehrotra et al. | Exciting new advances in oral cancer diagnosis: avenues to early detection | |
| Drezek et al. | Autofluorescence microscopy of fresh cervical‐tissue sections reveals alterations in tissue biochemistry with dysplasia¶ | |
| Kamemoto et al. | Near-infrared micro-Raman spectroscopy for in vitro detection of cervical cancer | |
| Biesterfeld et al. | Feulgen staining remains the gold standard for precise DNA image cytometry | |
| Mehrotra | The role of cytology in oral lesions: a review of recent improvements | |
| US11668653B2 (en) | Raman-based immunoassay systems and methods | |
| Islam et al. | Anatomic site based ploidy analysis of oral premalignant lesions | |
| Guo et al. | Molecular analyses of aspirated cystic fluid for the differential diagnosis of cystic lesions of the pancreas: a systematic review and meta-analysis | |
| Bremmer et al. | Comparative evaluation of genetic assays to identify oral pre‐cancerous fields | |
| US20220357276A1 (en) | Amyloid beta oligomer detection method, amyloid beta oligomer detection device, and amyloid beta oligomer detection program | |
| US10718694B2 (en) | Counterstains for a biological sample | |
| Bhat et al. | Protein profile analysis of cellular samples from the cervix for the objective diagnosis of cervical cancer using HPLC-LIF | |
| Matsui et al. | Label‐free multiphoton excitation imaging as a promising diagnostic tool for breast cancer | |
| CN107847145B (zh) | 光子结构和化学计量学病理系统 | |
| Castellanos et al. | Diagnostic imaging of cervical intraepithelial neoplasia based on hematoxylin and eosin fluorescence | |
| US20120264110A1 (en) | Automated pap screening using a plurality of biomarkers and multi-spectral imaging | |
| CA2842464C (fr) | Systeme et procede d?analyse d?echantillons marques au moyen de la 5, 10, 15, 20 tetrakis (4-carboxyphenyle) porphine (tcpp) | |
| Linden et al. | Flow cytometric prescreening of cervical smears. | |
| Abdul | Role of Advanced Diagnostic Aids in the Detection of Potentially Malignant Disorders and Oral Cancer at an Early Stage | |
| Bederka et al. | Sputum analysis by flow cytometry; an effective platform to analyze the lung environment | |
| Hemstreet III et al. | Quantitative fluorescence image analysis in bladder cancer screening | |
| Habibalahi et al. | Pterygium and ocular surface squamous neoplasia: optical biopsy using a novel autofluorescence multispectral imag-ing technique. Cancers. 2022; 14: 1591 | |
| O'Dea | Raman microspectroscopy for the discrimination of thyroid and lung cancer subtypes for application in clinical cytopathology | |
| Cahill | Rapid evaluation of pathology using nonlinear microscopy with applications in breast cancer, prostate cancer, and renal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150716 |